
Opinion|Videos|December 17, 2024
Testing Methodologies and Standards in Metastatic NSCLC
Author(s)Heather A. Wakelee, MD, FASCO, Jacob Sands, MD
Panelists discuss the various tests available for detecting genetic mutations in advanced non–small cell lung cancer (NSCLC), including next-generation sequencing (NGS), reverse transcription polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and Sanger sequencing, and explore whether one method is considered the “gold standard” according to the NCCN guidelines. They also address the appropriate use of circulating tumor DNA (ctDNA) testing, comparing it to tissue testing in this disease state.
Advertisement
Episodes in this series

- Dr Sands to Dr Wakelee: What tests are available for detecting genetic mutations (ie, NGS, RT-PCR, FISH, IHC, Sanger, etc) in advanced NSCLC?
- Is one considered the “gold standard” or preferred compared with the others?
NCCN Guidelines Version 10.2024 Non-Small Cell Lung Cancer - Dr. Wakelee: Describe when circulating tumor DNA (ctDNA) testing is appropriate.
- How does it compare to tissue testing in this disease state?
Advertisement
Related to this article

Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.

A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.

Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.

Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.

Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.

Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.

Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Advertisement
Advertisement
Trending on OncLive
1
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
2
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
3
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5


